Given the common endpoint of Aβ plaques and tau NFTs, there is strikingly little molecular and even less genetic data to explain why some EOAD patients develop syndromes such as lvPPA, frontal AD, or CBS, while others develop the more frequently observed amnestic phenotype. Here, MAPT is linked to Alzheimer disease.